Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Cancer
- Head and Neck Neoplasms
- Head and Neck Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Enrollment into each cohort will occur independently in a non-randomized fashion, based on PD-L1 expression results. Patients may not crossover between cohorts.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is an open-label, non-randomized study of approximately 80 patients. Enrollment into each cohort will occur independently, with 50 programmed cell death ligand 1 (PD-L1)-positive patients enrolled in the retifanlimab cohort, and 30 PD-L1-negative patients enrolled in the tebotelimab cohort.
This is an open-label, non-randomized study of approximately 80 patients. Enrollment into each cohort will occur independently, with 50 programmed cell death ligand 1 (PD-L1)-positive patients enrolled in the retifanlimab cohort, and 30 PD-L1-negative patients enrolled in the tebotelimab cohort.
Tracking Information
- NCT #
- NCT04634825
- Collaborators
- Not Provided
- Investigators
- Study Director: Fernanda Arnaldez, MD MacroGenics
Get Well Soon